ĀÜĄņĀŅĀ×

Dr. Bilsel brings nearly 15 years of corporate biotechnology and management experience in vaccine research against infectious diseases. Prior to joining FluGen, she was involved in developing DNA vaccines based on cell mediated immunity against influenza and malaria at Pharmexa-Epimmune where she served as Director of Molecular Biology.

At Pentamer Pharmaceuticals, a San Diego start-up venture, she worked on subunit vaccines against respiratory syncitial virus using virus-like particle technology. Preceding that Dr. Bilsel worked at Aviron generating live attenuated influenza vaccine strains in addition to studies with the cold-adapted influenza vaccine which was eventually launched as MedImmuneā€™s FluMistĀ®.

Dr Bilsel received her Ph.D. in Cell and Molecular Biology from the University of Nevada, Reno and did her post-doctoral training at St. Jude Childrenā€™s Research Hospital with Dr. Kawaoka.